Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Cash & Equivalents (2021 - 2025)

Senti Biosciences has reported Cash & Equivalents over the past 5 years, most recently at $16.4 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $16.4 million for Q4 2025, down 66.05% from a year ago — trailing twelve months through Dec 2025 was $16.4 million (down 66.05% YoY), and the annual figure for FY2025 was $16.4 million, down 66.05%.
  • Cash & Equivalents for Q4 2025 was $16.4 million at Senti Biosciences, up from $12.2 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for SNTI hit a ceiling of $139.8 million in Q2 2022 and a floor of $10.5 million in Q3 2024.
  • Median Cash & Equivalents over the past 5 years was $36.8 million (2023), compared with a mean of $46.8 million.
  • Biggest five-year swings in Cash & Equivalents: surged 68.55% in 2022 and later crashed 73.71% in 2023.
  • Senti Biosciences' Cash & Equivalents stood at $56.0 million in 2021, then increased by 2.83% to $57.6 million in 2022, then tumbled by 37.7% to $35.9 million in 2023, then soared by 34.54% to $48.3 million in 2024, then crashed by 66.05% to $16.4 million in 2025.
  • The last three reported values for Cash & Equivalents were $16.4 million (Q4 2025), $12.2 million (Q3 2025), and $21.6 million (Q2 2025) per Business Quant data.